PRINCETON, N.J., and PARIS — STENTYS S.A. announced today that it has received a higher price reimbursement in Germany for its drug-eluting stent.

“This decision not only fortifies our ongoing commercialization activities in Germany, the largest European market,” said Gonzague Issenmann, CEO and co-founder of STENTYS, “but it is also a clear recognition of the innovation and patient benefit of the STENTYS technology.”

The Institute for the Hospital Remuneration System (InEK) granted this special status of “new and innovative device” (Neue Untersuchungs- und Behandlungsmethoden, or “NUB”) to the STENTYS stent for 2011.

Of note: the STENTYS self-apposing stent represents a major breakthrough compared to conventional stents when treating heart attacks: it “fits snugly” into the contour of a blood vessel and adapts to the anatomic changes of the coronary arteries during the post-AMI phase, eliminating malapposition which exposes patients to serious risk of recurrence of the heart attack.

Source: STENTYS